Details

Autor(en) / Beteiligte

• Pulido, Tomás
• Adzerikho, Igor
• Channick, Richard N
• Delcroix, Marion
• Galiè, Nazzareno
• Ghofrani, Hossein-Ardeschir
• Jansa, Pavel
• Jing, Zhi-Cheng
• Le Brun, Franck-Olivier
• Mehta, Sanjay
• Mittelholzer, Camilla M
• Perchenet, Loïc
• Sastry, B.K.S
• Sitbon, Olivier
• Souza, Rogério
• Torbicki, Adam
• Zeng, Xiaofeng
• Rubin, Lewis J
• Simonneau, Gérald

Titel

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

Ist Teil von

• The New England journal of medicine, 2013-08, Vol.369 (9), p.809-818

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• In an event-driven trial, macitentan (an endothelin-receptor antagonist) at a dose of 3 or 10 mg was compared with placebo in patients with symptomatic pulmonary arterial hypertension. At a median of 115 weeks, both macitentan doses were associated with reduced morbidity and mortality. Pulmonary arterial hypertension, a severe disease characterized by a sustained elevation of pulmonary vascular resistance, ultimately leads to right heart failure and death. 1 Disease progression occurs despite the availability of drugs that are specific for the disorder. 2 Endothelin-receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin and its analogues have been approved for the treatment of pulmonary arterial hypertension and adopted clinically on the basis of short-term trials (12 to 16 weeks) that have shown improvements in exercise capacity as measured by the distance walked in 6 minutes. 3 – 10 However, current guidelines suggest that the primary end point in phase 3 . . .